| Biomarker ID | 605 |
| PMID | 21367627 |
| Year | 2011 |
| Biomarker | vascular endothelial growth factor (VEGF) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Patients with low levels survived longer than those with high levels |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: 4.640 (95% CI: 2.438–8.830); Multivariate Analysis: HR: 4.177 (95% CI: 2.168–8.045) |
| Effect on Pathways | Pathways Inlude:- S1P/S1P3 pathway,VEGFR1 pathway,Heart development,Actions of nitric oxide in the heart,Fibroblast growth factor 1 |
| Experiment | Prostate Cancer Specific Survival VS No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 148 CaP patients who underwent radical prostatectomy for clinically localized disease and 10 samples of benign prostatic hyperplasia (BPH) were chosen for the study. Lymph Node Metastatis Posititve(n=10) and Lymph Node Metastatis Negative (n=138) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p<0.001; Multivariate: p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | VEGFA |